Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting
Evoke will feature two poster presentations highlighting the use ofGimoti®(metoclopramide) nasal spray in patients. Notably, one of these abstracts, Poster P3339, has been honored with the prestigiousACG’s
Poster Presentation Details:
- Poster Number:P1606
- Session Time:
Sunday, October 27, 2024 ,3:30 p.m. –7:00 p.m. ET - Presenting Authors:
Richard McCallum , MD andMichael Cline , DO.
- Session Time:
- Poster Number:P3339
- Session Time:
Monday, October 28, 2024 ,10:30 a.m. –4:15 p.m. ET - Presenting Author:
David Kunkel , MD
- Session Time:
Evoke will also exhibit at ACG, unveiling a newly expanded exhibit booth and introducing our new marketing campaign for GIMOTI. It will be prominently showcased at location #361 in the ACG Exhibit Hall. Please join members of the management and commercial team to learn more about GIMOTI.
About
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in
Visitwww.EvokePharma.comfor more information.
Follow Evoke Pharma onLinkedInFollow Evoke Pharma onTwitter
Investor & Media Contact:
Tel: 862-213-1398
Source: Evoke Pharma, Inc.